NCT06674343View on ClinicalTrials.gov

Furmonertinib 160mg as First-line Treatment in Locally Advanced or Metastatic NSCLC With EGFR Classical Mutations

PHASE3RecruitingINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions
Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
DRUG

Furmonertinib

Furmonertinib 160mg, once daily, orally. Other Names: AST2818

Trial Locations (1)

100730

RECRUITING

Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER